Sign Out
There is no incidence of NALDEBAIN administering overdose in clinical trial. The drug is supplied in 2-mL vial for single dose usage with no risk of overdosage.
The suggestion for overdosage is immediate intravenous administration an opiate antagonist such as naloxone or nalmefene is a specific antidote. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated.
The administration of single doses of 72 mg of nalbuphine subcutaneously to eight normal subjects has been reported to have resulted primarily in symptoms of sleepiness and mild dysphoria.
Continue with Google